Introduction
Graft-versus-host disease (GVHD) is a major complication occurring after allogeneic hematopoietic stem cell transplantation (HSCT). GVHD manifests itself as a progressive, systemic disease that mostly affects the intestines, liver, lung, and skin (1) . Despite significant improvements in patient care, GVHD development remains the major limiting factor in the success of allogeneic hematopoietic cell transplantation (allo-HCT) for the treatment of hematologic malignancies, leading to significant transplant-related morbidity and mortality (2) . GVHD is characterized by the increased production of inflammatory cytokines and activation and expansion of alloreactive donor T cells in conjunction with the failure of existing regulatory mechanisms to counterbalance this proinflammatory milieu (3) (4) (5) . Patient conditioning regimens as well as Th1-type cytokines produced by allogeneic T cells are the driving forces contributing to the initiation and development of GVHD (2) (3) (4) (5) (6) . Thus, strategies designed to impede the pathogenesis of GVHD by regulating alloreactive donor T cell expansion and inflammatory cytokine productions are highly desirable.
Sphingolipids are highly bioactive molecules that can greatly influence cellular signaling and disease pathogenesis (6) . Currently, they are known mediators of apoptosis, proliferation, growth arrest, and inflammation (7) . Ceramides form the backbone to several complex sphingolipids, such as sphingomyelins and glucosylceramides, which can be generated by de novo synthesis or by degradation of complex sphingolipids. A key rate-limiting step in the biosynthesis of ceramides is the attachment of various acylCoA side chains to a sphingoid base by ceramide synthases. The ceramide synthases (CerS1-CerS6) act in a chain length-specific manner and introduce side chains to form C14-C30 ceramides. Briefly, CerS1 synthesizes C18-Cer, CerS4 synthesizes C18-/C20-Cer, CerS5 and CerS6 primarily synthesize C16-Cer, CerS2 mainly synthesizes C22/C24-Cer, and CerS3 synthesizes ultra-long-chain ceramides (8) . In addition to de novo synthesis, the salvage pathway also supplies ceramides, mainly via the activation of sphingomyelinases (SMase) (7) .
Although T cell metabolism, such as glycolysis and oxidative phosphorylation, has been studied extensively (9) , sphingolipid metabolism in T cell activation and function is much less characterized. Recent findings indicate that ceramides play important roles in inflammatory processes, and it has been shown that host acid SMase are imperative for maximal GVHD-associated pathology (10) . In the aforementioned study, lack of host acid SMase reduced the acute inflammatory phase of GVHD, attenuating the cytokine storm (10) . In the inflammatory disease cystic fibrosis, ceramides induce the upregulation of proinflammatory mediators, albeit via an unknown mechanism (11) . Importantly, CerS6-generated ceramides were shown to specifically contribute to the inflammatory process in the initial phase of experimental autoimmune encephalomyelitis (EAE) (12) . Thus, evidence exists to support the role of specific ceramides in inflammatory processes (12, 13) . However, the role of CerS6-generated ceramides in modulating T cell alloresponses in GVHD and graft-versus-leukemia (GVL) activity has not been elucidated. In the current study, we demonstrate that the absence of CerS6 in donor T cells significantly reduces GVHD. This reduction in GVHD was correlated with reduced T cell proliferation and responses of proinflammatory cytokines, namely IFN-γ. Mechanistically, we observed that CerS6 is critical for optimal TCR signal transduction and defects in CerS6 expression lead to reduced tyrosine phosphorylation and CD3-PKCθ colocalization. Furthermore, application of the CerS6/S4 inhibitor, ST1072, was used to confirm its role in T cell proliferation and proinflammatory cytokine production both in mouse and human cells after allostimulation. Thus, our study provides biological insights into the function of CerS6 as well as rationale to target CerS6 for the control GVHD after allogeneic BM transplantation (allo-BMT).
Results
CerS6 promotes allogeneic T cell responses. Ceramide syntheses play a critical role in inflammatory processes (12, 14) and are involved in many autoimmune diseases (12, 15) . However, how ceramide syntheses regulate activation and function of primary T cells is largely undefined. To address this question, we initially evaluated the role of CerS4 and CerS6 in T cell responses. For this purpose, we characterized T cell development and phenotype in WT, CerS4 KO, and CerS6 KO mice on a B6 background. In the thymus, while T cell compartments were similar in WT and CerS4 KO mice, a significant increase in percentages of CD4 Ceramides are critical for inflammatory responses (16) . In the inflammatory disease cystic fibrosis, ceramides induce the upregulation of proinflammatory mediators (11) . In addition, C16-ceramide (C16-cer) generated by CerS6 is involved in the induction of EAE through activation of NO/TNF-α synthesis (12) . Therefore, we next sought to test whether, or how, CerS6 or CerS4 affects T cell activation and function. Upon alloantigen stimulation in vitro, CerS6 KO T cells, both CD4 + and CD8 + , had a substantially reduced ability to proliferate and produce IFN-γ compared with WT counterparts, as reflected by the percentage of CFSE-diluted cells (Supplemental 
CerS6 is essential for T cells to induce GVHD.
Given that CerS6 KO T cells displayed a reduced allogeneic response in vitro and in vivo, we further hypothesized that CerS6 is essential for T cells to induce GVHD. Since naive and memory T cells have a distinct ability to induce GVHD and the proportion of naive and memory T cells was different in CerS6 KO and WT controls (Figure 1 ), we removed CD44 + memory T cells prior to BMT and compared naive T cells in the subsequent experiments. In a major MHC-mismatched B6→BALB/c BMT model, we found that recipients of WT T cells developed severe and lethal GVHD, whereas the majority of the recipients of CerS6 KO T cells survived long term and had significantly less weight loss and a reduced clinical score ( Figure 3A) . We have done this analysis extensively and substantiated the effect of CerS6 on different strains of mice by using a haploidentical BMT model. Similar results were also observed in a clinically relevant, haploidentical BMT model (B6→BD2F1) ( Figure 3B ). In contrast, CerS4 KO T cells had a comparable ability to WT T cells to induce GVHD (Figure 3 ). Taken together, CerS6 positively regulates both T cell responses to alloantigen and GVHD development.
Given that CerS4 had no observable effect on T cell allogeneic response and GVHD development, we decided to focus exclusively on the role of CerS6 in T cells and GVHD from this point forward. To test whether CerS6 affects T cell-mediated GVL activity, we infused host-type B cell lymphoma (A20) together with BM or BM plus T cells into BALB/c recipients. As expected, all the recipients without T cell infusion Figure 4D ). In contrast, 45%-50% recipients of CerS6 KO T cells survived without GVHD and were largely free from tumor relapse. Taken together, these data suggest that the CerS6 KO T cells were partially able to preserve GVL activity in an MHC-mismatched BMT model.
CerS6 regulates T cell expansion and migration. Development of GVHD requires donor T cell expansion in lymphoid organs and migration into target organs (17) . Hence, we asked whether CerS6 is required for T cell infiltration and expansion into target organs. Three weeks after BMT, we observed that recipients of CerS6 KO T cells had significantly fewer pathological injuries in the liver and colon ( Figure 5A ), which was consistent with the GVHD outcome presented in Figure 3 . We next examined the presence of donor T cells in recipient spleens (secondary lymphoid organ) and livers (GVHD target organ) 3 weeks after allo-BMT. Comparable numbers of CerS6 KO and WT T cells were found in recipient spleens ( Figure 5 , B-F); although a lower percentage of CerS6 KO T cells produced IFN-γ, suggesting that the CerS6 KO T cells had a reduced ability to differentiate into Th1 cells. In contrast, a significantly lower number of CerS6 KO CD4 + T cells was found in recipient livers as compared with that of WT T cells. In addition, T cells that migrated into the liver expressed significantly reduced levels Proximal TCR signaling is impaired in CerS6 KO T cells. TCR signaling dictates T cell response to cognate antigen. At the molecular level, we asked whether CerS6 affects TCR signaling. To address /mouse for BALB/c or 2 × 10 6 / mouse for BD2F1) from WT, ceramide synthase 4 (CerS4) KO, or ceramide synthase 6 (CerS6) KO B6 mice. BALB/c and BDF1 recipients were monitored for body weight change, survival, and clinical score until 80 days after BMT (n = 5 per group). Data shown are from 1 of 3 independent experiments for BALB/c mice. For comparison of recipient survival among groups, the log-rank test was used to determine statistical significance. Clinical scores and body weight loss were compared using a nonparametric Mann-Whitney U test. *P < 0.05, **P < 0.01. this question, we stimulated WT and CerS6 KO splenocytes with anti-CD3 at various time points and measured total tyrosine phosphorylation. CerS6 KO T cells had reduced levels of tyrosine phosphorylation compared with WT T cells ( Figure 6A ), suggesting that TCR signaling was impaired in the absence of CerS6. Similarly, we observed that tyrosine phosphorylation of a 70-kDa protein was impaired in the CerS6 KO cells after anti-CD3 stimulation ( Figure 6A ) and reasoned that it was ZAP-70, a key kinase for TCR signal transduction. Indeed, ZAP-70 was strongly phosphorylated and associated with CD3ζ after TCR stimulation in WT, but not CerS6 KO ( Figure 6B ). T cell activation is associated with translocation of PKCθ from the cytosol to the membrane (20, 21) . It is also reported that PKCθ can translocate to membrane rafts and that these rafts localize to the synapse formed upon contact between T cells and APCs (22) . We therefore asked if CerS6 affects PKCθ expression and colocalization with the TCR. Upon stimulation with anti-CD3, more PKCθ colocalized with CD3 in WT T cells than in CerS6 KO T cells ( Figure 6 , C and D). These data indicate that CerS6 affects T cell activation and function by regulating early TCR signaling.
Effect of CerS6 KO on lipid metabolism. The data presented thus far indicate that CerS6 is critical for optimal T cell activation and function. We sought to investigate how CerS6 affects sphingolipid metabolism during T cell response. Using a comprehensive lipidomics analysis, we found that C16-cer was the only sphingolipid metabolite that significantly increased after allostimulation in WT T cells; yet this increase was not present in CerS6 KO T cells ( Figure 7A) .
Furthermore, since we observed that CerS6 was required for optimal TCR signaling ( Figure 6 ), we asked whether lack of C16-cer was responsible for impaired TCR signaling in CerS6 KO T cells. To address this question, a gain-of-function approach was used, in which synthesized C16-cer was added into the cell culture. While additional C16-cer had little or no effect on CD3/PKCθ colocalization in WT T cells ( Figure 7B vs. Figure 6C) , it dramatically increased CD3/PKCθ colocalization in CerS6 KO T cells, especially at 15 minutes after TCR stimulation ( Figure 7C vs. Figure 6D ). The data suggest that an experiments (n = 6-7 per group for WT and CerS6 KO). For comparison of recipient survival among groups, the log-rank test was used to determine statistical significance. Clinical scores and body weight loss were compared using a nonparametric Mann-Whitney U test. ***P < 0.001.
inability to increase C16-cer might be responsible for the impaired function of CerS6 KO T cells ( Figures  2, 5 , and 6 and Supplemental Figure 4) .
C16-cer affects T cell proliferation and cytokine production. To further define the effect of C16-cer on T cell activation and function, we tested whether C16-cer could restore the T cell response in CerS6-deficient T cells. Indeed, additional C16-cer restored the proliferation capacity of CerS6 KO CD4 + T cells to that of WT counterparts in vitro (Supplemental Figure 5) . To extend this observation to T cell responses in vivo, we transplanted WT or CerS6 KO T cells into irradiated allogeneic recipients and tested the effect of C16-cer administration. Consistent with in vitro results, C16-cer increased proliferation of CerS6 KO T cells, although not significantly, given that allogeneic T cells proliferated much faster in vivo (Figure 8, A-C) . Albeit, C16-cer significantly increased the percentage of IFN-γ + cells in both CD4 + and CD8 + T cells in CerS6 KO, but not WT, T cells (Figure 8, D and E) . These results indicate that CerS6 is required for optimal T cell activation, proliferation, and cytokine production in allogeneic responses to C16-cer. ) cells in recipient spleens and (E and F) for livers, respectively. Data shown are from 2 independent experiments (n = 6). Significance was determined by ANOVA (A) and Student's t tests (for C and D). *P < 0.05, **P < 0.01, ***P < 0.001.
Inhibition of CerS6 reduces T cell response to alloantigen.
We have demonstrated that CerS6 promotes T cell responses to alloantigen and thus GVHD development. We hypothesized that pharmacologic inhibition of CerS6 would have a similar effect on allogeneic T cell responses. To test this hypothesis, we evaluated the effect of the CerS6/S4 inhibitor, ST1072 (23), on T cell responses after allogeneic stimulation. As shown in Figure 9 , ST1072 significantly reduced the ability of murine T cells to proliferate ( Figure 9 , A and C) and produce IFN-γ ( Figure 9, B and D) . To assess the specificity of ST1072, we tested its effect on CerS6 KO T cell responses after allogeneic stimulation. While ST1072 inhibited cell proliferation of WT T cells in a dose-dependent manner, it had a minimal effect on CerS6 KO T cells (Supplemental Figure 6, A and B) . For translational purposes, we sought to extend this observation to human T cells. Consistent with the observed results in murine T cells, we found that inhibition of CerS6/S4 significantly lowered the proliferation and IFN-γ production of human CD4 + T cells in response to alloantigen stimulation in vitro (Figure 9 , E-G). These results indicate that CerS6 can be pharmacologically targeted to regulate T cell activation and function.
Discussion
Sphingolipids are known to play essential roles in the induction and progression of inflammation (24) , but how specific ceramides regulate inflammation and immune responses is largely undefined (12, 13) . To our knowledge, we show for the first time that CerS6 and its product C16-cer contribute to inflammation by inducing T cell proliferation and IFN-γ production. In addition, we found that CerS6 ablation reduced T cell alloresponses in the initial phases of GVHD and also that targeting this molecule is efficacious in reducing the severity of colitis, implying that CerS6 blockade could be therapeutically applicable to autoimmune disorders. Using primarily genetic and pharmacologic approaches, our data demonstrate that CerS6 governs multiple aspects of the T cell response to alloantigen, though not under hemostatic conditions. CerS6 strongly enhances activation and proliferation of T cells, and the expression of CerS6 on donor T cells is essential for the induction of GVHD after allo-BMT. Hence, pharmacologic blockade (using ST1072) Figure 7 . Effect of ceramide synthase 6 on lipid metabolism. (A) T cells from WT or ceramide synthase 6 (CerS6) KO mice were stimulated with allogeneic APCs for 5 days, and unstimulated T cells were used as controls. These T cells were subjected to mass spectrometry HPLC-MS analysis for different ceramide species. Data shown are from 3 independent experiments (n = 9). Splenocytes from (B) WT or (C) CerS6 KO mice were incubated with C16-cer for 1 hour at 37°C and were either left unstimulated or subjected to TCR engagement for the indicated time points. Cells were then stained for CD3 and PKCθ expression, followed by analysis with confocal microscopy (original magnification, ×63). Data shown are from 1 representative experiment of 3 independent experiments. Significance was determined by ANOVA test. **P < 0.01, ***P < 0.001.
of CerS6 represents a potential approach for attenuating GVHD in a clinical setting. Mechanistically, T cells deficient in CerS6 had a dramatically decreased ability to expand, which correlated with a reduced proliferation capacity during alloantigen-driven responses in vivo. This observed reduction in proliferation can be linked to reduced tyrosine phosphorylation and impaired colocalization of CD3-PKCθ ( Figure 6 , A-C) in CerS6 KO T cells after TCR stimulation. From these data, it is plausible to predict that inhibition of CerS6 could specifically, or preferentially, suppress alloantigen-driven responses while preserving T cell homeostasis, a highly coveted benefit that would alleviate GVHD without causing broad immune suppression in patients undergoing allo-HCT.
T cell phenotypes are critical to GVHD pathogenesis. Previous studies have shown that donor memory T cells alone are incapable of inducing GVHD (25, 26) , while naive CD4 T cells possess an enhanced ability to cause GVHD (25, 26) . Hypothetically, the TCR repertoire could be altered such that the immunodominant miHAs targeted by naive T cells are not recognized by memory cells (26) . CerS6 KO naive donor T cells had a reduced ability to cause GVHD, suggesting the involvement of CerS6 on T cell function. It has been reported that a decrease in TCR expression levels leads to a reduction in T cell response following TCR stimulation (27) . TCR affinity could be another factor, as the presence of a strong or weak TCR leads to proinflammatory or antiinflammatory responses, respectively (28) . Many biological aspects influence . Data shown are from 1 representative experiment of 2 independent experiments. Significance was determined by ANOVA test for (C, E, and F). *P < 0.05, **P < 0.01, ***P < 0.001. the polarization of T cells, including factors collectively termed "strength of stimulation," such as peptide dose and duration of TCR engagement (28) . Ceramides are known to modulate TCR responsiveness, and CerS6 KO T cells have a reduced TCR response, reflected by a reduction of tyrosine phosphorylation and TCR/CD3-PKCθ colocalization after TCR engagement. We hypothesized that CerS6 bioactivity could effect TCR repertoire/TCR affinity, which normally mediates T cell differentiation and Th cell responses (29, 30) . We demonstrated that genetic deletion or pharmacologic inhibition of CerS6 suppresses T cell proliferation and differentiation into Th1 cells both in vivo and in vitro, which supports our notion that the effect of C16-cer on TCR signaling is directly linked to T cell responses. It is commonly believed that donor T cell infiltration into target organs is a prerequisite for GVHD development. Chemokine receptors and integrins play important roles in T cell migration to GVHD target organs (29) . There were significantly fewer CerS6 KO T cells and proinflammatory cytokines in recipient livers than in their WT counterparts, even though chemokine and chemokine receptors, especially α4β7 and CXCR3, are comparable (data not shown). Decreased T cell expansion and/or migration to target organs likely contributed to the reduced pathogenicity of CerS6 KO T cells during the induction of GVHD. Of clinical relevance, we demonstrated that CerS6 KO T cells were partially dispensable for the T cell-mediated GVL effect in a preclinical BMT model. The effect of CerS6 deficiency was obvious not only in allogeneic BMT models, but also in a syngeneic T cell transfer model of colitis. These observations further support the notion that TCR responsiveness in CerS6 KO T cells was reduced. These data are consistent with distinct functions of ceramides with various different fatty acid chain lengths generated by CerS1-CerS6 (31). For example, while CerS2/ C24-ceramide is implicated in the regulation of liver function (32), CerS1-generated C18-ceramide is associated with nervous system physiology and function through the regulation of Purkinje cells (33) . CerS3- Significance was determined by Student's t test. *P < 0.05, **P < 0.01, ***P < 0.001. generated ultra-long sphingolipids play key roles in the homeostasis of skin barrier function (34) , whereas deficiency of CerS4 is associated with skin disorders such as irreversible alopecia (35, 36) .
The regulation of TCR expression is an important mechanism by which T cell responsiveness is controlled, and membrane rafts are the "effector" sites in T cell signaling (37) . Upon stimulation, these rafts cluster into an immunological synapse (38, 39) that harbors key proteins, including TCR, CD3, PKCθ, ZAP-70, etc. (40, 41) . The synapse is believed to sustain TCR engagement and T cell signaling (22) . Reports have shown that ceramides influence cell fate by participating in various signaling pathways, either through modulation of lipid rafts or through direct interaction with downstream effectors. TCR upregulation was long lasting in the presence of ceramide, but, following its removal, TCR expression quickly returned to baseline levels (27) . Ceramide induced TCR upregulation in a concentration-and time-dependent manner. Treatment with high concentrations (>10 μM) induces cell apoptosis (42) , whereas low titration (<1 μM) initiates intracellular Akt activation (43) . However, recent studies have shown that exogenous ceramide has no detectable effect after a single treatment (44) , although increased expression of CerS6 preferentially generates C16-cer (45) . Yet, the effect of exogenous C16-cer was quite evident on CerS6 KO T cells; they showed a marked increase in proliferation both in vivo and in vitro. The in vivo supplementation of C16-cer also increased production of proinflammatory cytokines, especially IFN-γ, in CerS6 KO donor T cells. In contrast, WT T cells remained grossly unchanged in the presence or absence of C16-cer in both cases. We reason that the level of endogenous ceramide in WT T cells significantly increased upon allostimulation and might have reached saturation level ( Figure 7A ). On the contrary, CerS6 KO T cells failed to show any increase in endogenous C16-cer ( Figure 7A ) after allostimulation, suggesting that additional supplementation of C16-cer augments T cell activation, proliferation, and proinflammatory responses.
It is clear from both previous (12) and current observations that CerS6-generated C16-cers play a critical role in regulating different immune cells, including macrophages and T cells, which in turn can modulate different autoimmune diseases, such as EAE, GVHD, and colitis. Our study establishes that CerS6 and its products markedly influence the pathogenesis of GVHD and that pharmacologically targeting this pathway could be a novel therapeutic strategy in the clinic. We show that blockade of CerS6/S4 via an inhibitor (ST1072) significantly reduced T cell proliferation and proinflammatory responses under allogeneic stimulation and that this was consistent in both mouse and human T cells (Figure 9 , A-D). Although this inhibitor is known to be specific for CerS6 and CerS4 (23), we observed that CerS4 had a minimal effect on T cell activation and function during an allogenic response and, subsequently, on GVHD, suggesting that the effect of this inhibitor is due to inhibition of CerS6. T cell phenotypes after CerS6 inhibition and in CerS6 KO T cells had similar effects on proliferation and proinflammatory cytokine production, further suggesting that the preventative role of this inhibitor in GVHD is more pertinent to CerS6 blockade, which can be used to attenuate the severity of GVHD while preserving GVL activity. However, in order for further characterization of ceramide synthases, it is imperative to have specific inhibitors for each ceramide synthase, including CerS6.
In conclusion, we observed that TCR engagement upregulates CerS6, which results in de novo generation of C16-cer, which in turn modulates TCR activity by participating in various signaling pathways, either through modulation of lipid rafts and/or through direct interaction with downstream effectors. This signaling promotes activation of ZAP-70 and colocalization of PKCθ with the TCR, leading to allogeneic T cell activation, proliferation, migration, and proinflammatory cytokine production, which ultimately leads to GVHD development. Furthermore, inhibition of CerS6 using ST1072 reverses the stimulatory effect of CerS6 on T cells, as depicted in Supplemental Figure 7 . Therefore, we anticipate that, in the near future, the translational feasibility of specifically silencing (inhibiting) CerS6, which could significantly benefit patients with hematological malignancies undergoing allo-HCT, will be achieved.
Methods
Mice. C57BL/6 (B6; H-2 b , CD45.2), B6.Ly5.1 (CD45.1) BD2F1, BALB/c (H-2 d ), and Rag1 KO mice were purchased from the National Cancer Institute (Frederick, Maryland, USA) or Jackson Laboratories. CerS6 KO (46) and CerS4 KO mice on a B6 background were generated by Texas Institute for Genomic Medicine, College Station, Texas, USA. All animals were housed at the Medical University of South Carolina.
Mixed lymphocyte reaction. T cells were purified from B6, CerS4 KO, and CerS6 KO mice and labeled with CFSE (Invitrogen, Molecular Probes Inc.). For in vitro experiments, 0.2 × 10 6 T cells were cocultured with T cell-depleted 0.6 × 10 6 splenocytes for 5 days. For in vivo experiments, the T cells were injected i.v.
into irradiated recipient mice for 4 days. Recipient spleens were excised, and the cells were stained for T cell proliferation and different cytokines by flow cytometry.
BMT. T cells were purified from spleen and lymph node cells by negative selection using magnetic beads as previously described (14) . MHC-mismatched (B6→BALB/c) and haploidentical (B6→BD2F1) BMT models were used as previously established (15) . Briefly, 8-to 10-week-old recipient mice were conditioned with total body irradiation based on weight, at 650-700 cGy (single dose) for BALB/c mice and 1,100-1,200 cGy (split 3 hours apart) for BD2F1 mice using an X-RAD 320 x-ray irradiator (Precision X-Ray) at Medical University of South Carolina. Within 24 hours after conditioning, recipients were i.v. injected with T cell-depleted BM alone, with or without CD44/25-depleted T cells from WT or CerS6 KO donors. Recipient mice were monitored for weight loss and other clinical signs of GVHD twice per week. Clinical scores were tabulated as 5 parameters: weight loss, posture, activity, fur texture, and skin integrity. Individual mice were scored from 0 to 2 for each criterion and from 0 to 10 overall (16) . Recipients at the premoribund stage were euthanized and counted for lethality. Representative samples of GVHD target organs were excised from recipients 21 days after BMT and subjected to pathology scoring as previously described (14, 17) .
A GVL model was established by i.v. injecting luc/neo plasmid-transduced A20 B cell lymphoma cells (A20-luc) (ATCC) on a BALB/c background the day of BMT (2 × 10 3 A20 cells/mouse). Tumor growth was measured with bioluminescent imaging using a Xenogen IVIS 200 preclinical in vivo imaging system (PerkinElmer) and analyzed by Living Image software (PerkinElmer) as previously described (17) . Tumor and GVHD mortality were distinguished by bioluminescent imaging signal intensity and clinical manifestation of GVHD.
Histologic analysis. Representative samples of liver, small intestine, large intestine, lung, and skin were obtained from transplanted recipients 21 days after transplant, fixed in 10% neutral-buffered formalin, and washed with 70% ethanol. Samples were then embedded in paraffin, cut into 5-μm-thick sections, and stained with H&E. A semiquantitative scoring system was used to account for histologic changes consistent with GVHD in the colon, liver, and lung as previously described (47) . Data are presented for individual GVHD target organs. All slides for GVHD analysis were coded and read in a blinded fashion (48) .
Flow cytometry. Mononuclear cells were isolated from recipient spleens or livers, as previously described (14, 17, 18) , and stained for surface markers and intracellular cytokines using standard flow cytometric protocols. Stained cells were analyzed using FACSDiva software, LSR II (BD Biosciences) and FlowJo (Tree Star). The following antibodies were used for cell surface staining: anti-CD4-V450 (RM4-5), -APC, and -PEcy7 (BD Biosciences); anti-CD8-PEcy5 (53-6.7), -APCcy7, and -AF700 (BD Biosciences); anti-CD45.1-FITC (A20) and -APC (BD Biosciences); anti-B220-FITC (RA3-682) and -PE (eBioscience); anti-CD44-APC,PE (IM7) (eBioscience); anti-CD62L-Pecy5,-FITC (MEL-14) (eBioscience); CD25-FITC (7D4) and Pecy7 (PC 61.5) (eBioscience); and anti-H2Kb (AF6-88.5.5.3) (eBioscience). Intracellular staining was carried out using anti-IFN-γ-PE or Per-cp 5.5 (XMG1.2; BD Biosciences), anti-IL-4-PE (11B11; BD Pharmingen), anti-IL-5-PE (TRFK5; BD Pharmingen), and anti-Foxp3-PE (FJK-16s; eBioscience) and the appropriate isotype controls. Synthesis of LCL-2 D-erythro-N-PalmitoylSphingosine (D-e-C16-ceramide) was synthesized by the Lipidomics Shared Resource, Synthetic Unit, Medical University of South Carolina, as described previously (49, 50) .
HPLC-MS/MS analysis of sphingolipids.
Lipid extractions and analyses were performed by the Lipidomics Shared Resource, Analytical Unit, Medical University of South Carolina. Briefly, cells were lysed with RIPA buffer. Further preparation of samples and advanced analyses of endogenous bioactive sphingolipids were performed on a ThermoFisher TSQ Quantum liquid chromatography/triple-stage quadrupole mass spectrometer system, operating in a multiple reaction monitoring-positive ionization mode, as previously described (51) . Lipid levels were normalized to the level of protein present in samples (picomol/mg protein).
Immunoprecipitation and immunoblots. Primary splenocytes (7 × 10 6 cells) were incubated with 5 μg/ ml anti-CD3 (145-2C11) for 30 minutes at 4°C. The cells were washed with PBS and incubated with goat anti-hamster (1:100 dilutions) at 37°C for indicated time points. The reaction was stopped immediately by adding 1 ml ice-cold PBS containing 0.5 mM EDTA and 2 mM sodium pervanadate (Na 3 VO 4 ). Cells were washed with PBS and lysed for 45 minutes with lysis buffer containing Triton X-100 lysis buffer containing 50 mM Tris, pH 7.6, 150 mM NaCl, 50 mM NaF, 1 mM EDTA, 1.8 mg/ml iodoacetamide, and a mixture of protease inhibitors (aprotinin, pepstatin, and leupeptin) on ice followed by centrifugation at 16,000 g for 10 minutes at 4°C. The supernatant was incubated with protein A/G-Sepharose beads for 2 hours at 4°C
